ATRIAL FIBRILLATION AND CONGESTIVE HEART FAILURE: THE CASE FOR EARLY RHYTHM CONTROL

Atrial fibrillation (AF) and congestive heart failure (CHF) frequently coexist, and their combination carries a worse prognosis than either condition alone. This thesis argues that AF and CHF form a single, self-reinforcing pathophysiological cycle in which each disease provokes and worsens the other, so the optimal strategy is not to tolerate the arrhythmia through rate control but to interrupt the cycle early through rhythm control — principally catheter ablation — on a foundation of guideline-directed medical therapy, anticoagulation, and risk-factor modification. Early drug trials (AFFIRM, AF-CHF) showed no benefit from pharmacological rhythm control, but the CASTLE-AF and CASTLE-HTx trials later demonstrated that catheter ablation reduces mortality and heart-failure hospitalisation in patients with reduced ejection fraction — evidence now reflected in the 2023 ACC/AHA/ACCP/HRS Class 1 recommendation. Interrupting the cycle early, rather than managing its consequences late, is the most promising path to better outcomes.